StockVS

Zhongchao Inc. (ZCMD) Analyse boursière

Santé

Zhongchao Inc.

$1.45

+$0.02 (+1.40%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

Zhongchao Inc., identified by the ticker ZCMD, operates within the healthcare sector specifically as a provider of health information services. The company delivers healthcare information, education, and training services to healthcare professionals in the People's Republic of China under its MDMOOC brand. Its operational scope is segmented into two distinct areas: MDMOOC services and the sales of patented drugs, which also includes patient management services. With a market capitalization of $7.42M and annual revenue of $11.37M, the company functions on a small scale relative to large-cap peers. The combination of a sub-$10M market cap and single-digit million revenue stream indicates that Zhongchao Inc. occupies a niche position rather than a dominant market share. The absence of available employee data further suggests a lean operational structure typical of specialized service providers in the health information industry. These valuation metrics collectively position the entity as a micro-cap stock with limited operational footprint and specialized service offerings in the Chinese healthcare market.

Santé financière

Zhongchao Inc. reported a revenue of $11.37M over the trailing twelve months, yet it recorded a net income of $-6,310,153, revealing a severe disconnect between top-line generation and bottom-line profitability. The EBITDA stood at $-5,901,042, indicating that operating expenses significantly exceeded operating revenues before interest and taxes. This substantial gap between positive revenue and negative net income highlights a cost structure where operating costs, likely driven by high burn rates or significant one-time expenses, consume the majority of generated income. The company's free cash flow was $-1,112,632, demonstrating a lack of financial flexibility to fund capital expenditures or debt service from current operations without external financing. Despite generating negative operating cash flow, the balance sheet remains robust with cash holdings of $13.92M against a minimal debt load of $26,083. The debt-to-equity ratio of 0.12 confirms that the company maintains a highly conservative balance sheet with negligible leverage. Liquidity is exceptionally strong, evidenced by a current ratio of 11.11, which suggests the firm holds more than eleven times the current assets necessary to cover its short-term liabilities. However, the return on equity is -24.9% and the return on assets is -15.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate profits.

Évaluation de la valorisation

The trailing twelve-month P/E ratio is N/A due to the negative earnings, while the forward P/E is also N/A, meaning traditional earnings-based valuation multiples cannot be applied to assess the expected earnings trajectory. The price-to-book ratio stands at 0.30, indicating that the market values the company at significantly less than the replacement cost of its tangible assets. The price-to-sales ratio is 0.65, suggesting the market prices the revenue stream at less than two-thirds of its nominal value. The EV/EBITDA multiple is 0.42, an extremely low figure that reflects the negative earnings but also highlights the asset-heavy or cash-rich nature of the balance sheet relative to its valuation. The stock has exhibited significant volatility, with a 52-week high of $12.18 and a 52-week low of $1.44. Without a specific current share price provided in the facts, the range indicates a wide band of potential price discovery, though the low valuation multiples suggest the market has priced in the risk of continued losses. The beta is listed as N/A, preventing an assessment of price volatility relative to the broader market index. These alternative valuation metrics provide a clearer picture than earnings multiples, showing the market is focusing on asset value and sales generation rather than profitability.

Growth & Income

Zhongchao Inc. experienced a revenue growth rate of -23.2% year-over-year, while the earnings growth rate is N/A due to the lack of positive earnings history for calculation. The contraction in revenue implies that the company is shrinking its top line, and without positive earnings, the concept of earnings growing faster or slower than revenue is currently inapplicable. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its earnings, or rather its cash reserves, into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by declining revenue, negative earnings, and a non-dividend strategy that relies entirely on the $13.92M cash reserve to fund future operations and potentially reverse the negative revenue trend.

Comparaison avec les pairs

Zhongchao Inc. (ZCMD) opère dans le secteur Services d'Information Sanitaire. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
Zhongchao Inc. ZCMD $5.59M N/A
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

Le ratio P/E moyen du secteur Services d'Information Sanitaire est de 57.5x. Zhongchao Inc. se négocie à un P/E de N/A.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de Zhongchao Inc.

Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$5.59M
Ratio P/E
N/A
Plus Haut 52 Sem.
$12.18
Plus Bas 52 Sem.
$1.25
Volume Moyen
15.21K
Bêta
0.15

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NASDAQ
Pays
China
Employés
33